Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration

Nutr Rev. 2006 Aug;64(8):357-63. doi: 10.1111/j.1753-4887.2006.tb00220.x.


The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.

Publication types

  • Review

MeSH terms

  • Blood Glucose / drug effects
  • Diabetes Mellitus, Type 2 / epidemiology*
  • Diabetes Mellitus, Type 2 / prevention & control
  • Dietary Supplements
  • Evidence-Based Medicine*
  • Food Labeling*
  • Humans
  • Insulin Resistance
  • Picolinic Acids / therapeutic use*
  • Risk Factors
  • United States
  • United States Food and Drug Administration


  • Blood Glucose
  • Picolinic Acids
  • picolinic acid